• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ALSE
Share

Alseres Pharmaceuticals, Inc. Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

Performance

Very poor

Risk

Considerable

Recommendation

Sell

Market Cap

$ 398255

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.08.2026 00:26

Boeing has received regulatory approval for a smaller version of its most popular aircraft

03.08.2026 23:29

Shares of Cloud Giants Soared: Microsoft and Amazon Reassured Investors

03.08.2026 22:46

Earnings Reports from Palantir, SpaceX, and AMD Will Be a "Real-World Test" for the AI Rally — Saxo Bank

03.08.2026 22:30

The new "Spider-Man" brought AMC theaters record box office receipts in its 106-year history

03.08.2026 21:58

Aperol sales have fallen in the U.S. What does this mean for investors?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026